The Global Molybdenum-99 (Mo-99) Market was valued at USD 335 Million in 2024 and is projected to reach USD 476 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.3% during the forecast period (2025–2032). This growth is being driven by rising demand for diagnostic imaging procedures, an aging global population increasing the need for nuclear medicine, and the accelerating adoption of low-enriched uranium (LEU) production methods to ensure supply security across healthcare sectors worldwide.

As the nuclear medicine industry advances toward precise diagnostics and resilient supply chains, the spotlight is on the key isotope producers who are driving innovation, capacity expansion, and reliable distribution pathways. In this blog, we profile the Top 10 Companies in the Molybdenum-99 (Mo-99) Industry—a mix of nuclear research organizations, radiopharmaceutical specialists, and production pioneers shaping the future of global medical radioisotopes.

---

🔟 1. Rosatom

Headquarters: Moscow, Russia
Key Offering: Mo-99 via fission-based production, Tc-99m generators

Rosatom is a major global supplier of Mo-99, leveraging its extensive nuclear infrastructure to produce and distribute the isotope for diagnostic applications. The state corporation supports healthcare systems in Europe, Asia, and beyond with consistent supply, focusing on large-scale reactor-based production while exploring LEU transitions.

Production Initiatives:

• Expanding reactor capacity for stable Mo-99 output

• Partnerships for international distribution networks

• Research into enhanced processing for higher yields

Download FREE Sample Report: Molybdenum-99 (Mo-99) Market – View in Detailed Research Report

---

9️⃣ 2. NTP Radioisotopes

Headquarters: Pelindaba, South Africa
Key Offering: LEU-based Mo-99, radiopharmaceutical processing

NTP Radioisotopes, part of NECSA, accounts for about 16% of global supply and operates from the Safari-1 reactor. It plays a crucial role in exporting Mo-99 to North America and Europe, emphasizing reliable logistics for time-sensitive deliveries.

Production Initiatives:

• Fully transitioned to LEU targets

• Investments in supply chain resilience

---

8️⃣ 3. Curium Pharma

Headquarters: Paris, France
Key Offering: Mo-99/Tc-99m generators, distribution services

Curium is a leading provider of Mo-99 derived products, serving over 1,000 hospitals worldwide with generators and ensuring just-in-time delivery. The company bridges production and end-users through its global network and focus on quality control.

Production Initiatives:

• Strategic sourcing from multiple producers

• Advanced generator technology for efficiency

---

7️⃣ 4. NorthStar Medical Radioisotopes

Headquarters: Beloit, Wisconsin, USA
Key Offering: Non-uranium Mo-99, Tc-99m production

NorthStar is pioneering reactor-independent Mo-99 production using electron accelerators, reducing reliance on aging facilities. Its domestic U.S. approach addresses supply vulnerabilities while supporting over 10 million patient doses annually.

Production Initiatives:

• Commercial-scale accelerator facilities online

• U.S. government-backed LEU alternatives

Download FREE Sample Report: Molybdenum-99 (Mo-99) Market – View in Detailed Research Report

---

6️⃣ 5. SHINE Medical Technologies

Headquarters: Janesville, Wisconsin, USA
Key Offering: Accelerator-produced Mo-99, no highly enriched uranium

SHINE is developing innovative fusion-accelerator technology for domestic Mo-99 production, aiming to supply the U.S. market independently. The company focuses on sustainable, waste-minimizing methods compatible with existing generators.

Production Initiatives:

• Pilot facilities demonstrating viability

• Net-zero waste production targets

---

5️⃣ 6. IRE (Institut des Radioéléments)

Headquarters: Fleurus, Belgium
Key Offering: Fission-based Mo-99, LEU processing

IRE is a cornerstone European producer, operating the BR2 reactor for high-volume Mo-99 output serving major markets. It excels in chemical separation and distribution, contributing significantly to the 61% European market share.

Production Initiatives:

• 94% LEU adoption in new capacity

• Capacity over 1 million six-day curies weekly

---

4️⃣ 7. ANSTO (Australian Nuclear Science and Technology Organisation)

Headquarters: Lucas Heights, Australia
Key Offering: LEU Mo-99, global exports

ANSTO supplies about 18% of world Mo-99 from its OPAL reactor, focusing on high-reliability production and Asia-Pacific delivery. The organization leads in LEU technology, supporting 40 million annual Tc-99m procedures.

Production Initiatives:

• Consistent weekly production schedules

• Expansion to meet growing demand

---

3️⃣ 8. Canadian Nuclear Laboratories (CNL)

Headquarters: Chalk River, Ontario, Canada
Key Offering: Reactor-produced Mo-99, research isotopes

CNL utilizes the NRU reactor legacy and new facilities for Mo-99, supplying North American markets with emphasis on R&D for next-gen methods. It collaborates on non-proliferation compliant production.

Production Initiatives:

• Domestic supply chain development

• Alternative technology research

---

2️⃣ 9. Bruce Power

Headquarters: Tiverton, Ontario, Canada
Key Offering: LEU-based Mo-99 production

Bruce Power restarted commercial Mo-99 production at its CANDU reactors, providing a diversified North American source. The utility’s scale enables cost-effective supply for hospitals and imaging centers.

Production Initiatives:

• Large-scale LEU target irradiation

• Partnerships for processing and distribution

---

1️⃣ 10. NRG

Headquarters: Petten, Netherlands
Key Offering: High-volume LEU Mo-99, Tc-99m supply chain

NRG, operating the HFR reactor, is the world’s leading Mo-99 producer, supplying diverse global markets with reliable, high-purity isotope. It pioneered LEU methods and supports over 91% market control by top players.

Production Initiatives:

• Advanced LEU facilities producing millions of doses

• Collaborations for non-reactor alternatives

Read Full Report: Molybdenum-99 (Mo-99) Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Molybdenum-99 Is More Secure and Innovative

The Molybdenum-99 market is undergoing a vital transformation. While reactor-based production dominates, the industry is investing heavily in LEU technologies, alternative methods, and diversified supply networks to mitigate disruptions.

📈 Key Trends Shaping the Market:

• Rapid LEU capacity expansion in Europe, North America, and Australia

• Regulatory push for non-proliferation and domestic production

• Development of accelerator and cyclotron alternatives

• Global collaborations for supply chain resilience

Read Full Report: Molybdenum-99 (Mo-99) Market – View in Detailed Research Report

The companies listed above are not only supplying essential diagnostics—they’re spearheading the secure transition of nuclear medicine worldwide.